Incarceration and Cancer-Related Outcomes (ICRO) study protocol: using a mixed-methods approach to investigate the role of incarceration on cancer incidence, mortality and quality of care.

Autor:	Puglisi L; SEICHE Center for Health and Justice, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA lisa.puglisi@yale.edu., Halberstam AA; Yale University, New Haven, Connecticut, USA., Aminawung J; SEICHE Center for Health and Justice, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA., Gallagher C; Connecticut Department of Correction, Wethersfield, Connecticut, USA., Gonsalves L; Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, Connecticut, USA., Schulman-Green D; Rory Meyers College of Nursing, New York University, New York, New York, USA., Lin HJ; School of Social Work, University of Connecticut System, Storrs, Connecticut, USA.; Research Division, Connecticut Department of Mental Health and Addiction Services, Hartford, Connecticut, USA., Metha R; Yale Rapid Case Ascertainment, Yale Cancer Center, New Haven, Connecticut, USA., Mun S; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut, USA., Oladeru OT; Harvard Radiology Oncology Program, Brigham and Women's Hospital, Boston, Massachusetts, USA., Gross C; Department of Internal Medicine, Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut, USA., Wang EA; SEICHE Center for Health and Justice, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2021 May 25; Vol. 11 (5), pp. e048863. Date of Electronic Publication: 2021 May 25.
DOI:	10.1136/bmjopen-2021-048863
Abstrakt:	Introduction: Incarceration is associated with decreased cancer screening rates and a higher risk for hospitalisation and death from cancer after release from prison. However, there is a paucity of data on the relationship between incarceration and cancer outcomes and quality of care. In the Incarceration and Cancer-Related Outcomes Study, we aim to develop a nuanced understanding of how incarceration affects cancer incidence, mortality and treatment, and moderates the relationship between socioeconomic status, structural racism and cancer disparities. Methods and Analysis: We will use a sequential explanatory mixed-methods study design. We will create the first comprehensive linkage of data from the Connecticut Department of Correction and the statewide Connecticut Tumour Registry. Using the linked dataset, we will examine differences in cancer incidence and stage at diagnosis between individuals currently incarcerated, formerly incarcerated and never incarcerated in Connecticut from 2005 to 2016. Among individuals with invasive cancer, we will assess relationships among incarceration, quality of cancer care and mortality, and will assess the degree to which incarceration status moderates relationships among race, socioeconomic status, quality of cancer care and cancer mortality. We will use multivariable logistic regression and Cox survival models with interaction terms as appropriate. These results will inform our conduct of in-depth interviews with individuals diagnosed with cancer during or shortly after incarceration regarding their experiences with cancer care in the correctional system and the immediate postrelease period. The results of this qualitative work will help contextualise the results of the data linkage. Ethics and Dissemination: The Yale University Institutional Review Board (#2000022899) and the Connecticut Department of Public Health Human Investigations Committee approved this study. We will disseminate study findings through peer-reviewed publications and academic and community presentations. Access to the deidentified quantitative and qualitative datasets will be made available on review of the request. Competing Interests: Competing interests: CG has received research funding, though Yale, from the NCCN Foundation (Pfizer/Astra-Zeneca) and Genentech, as well as funding from Johnson & Johnson to help devise and implement new approaches to sharing clinical trial data, and funding from Flatiron for travel to and speaking at a scientific conference. All other authors report no competing interests. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu